{
  "run": {
    "id": "cmnr14g6704skp658hewo66ee",
    "region": "US",
    "assetId": "cmnr14g5m04sgp658pvrsh68h",
    "ticker": "LH",
    "snapshotId": "cmnr14g5q04sip658dz2cnmq6",
    "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux",
    "createdAt": "2026-04-09T05:21:17.789Z",
    "promptTemplate": {
      "id": "cmnqt07si0005lm3jzpxuu1ux",
      "name": "Oficial 08.apr.2026",
      "version": 1
    },
    "snapshot": {
      "id": "cmnr14g5q04sip658dz2cnmq6",
      "assetId": "cmnr14g5m04sgp658pvrsh68h",
      "asOf": "2026-04-08T20:00:02.000Z",
      "snapshot": {
        "asOf": "2026-04-08T20:00:02.000Z",
        "quote": {
          "asOf": "2026-04-08T20:00:02.000Z",
          "open": null,
          "price": 274.72,
          "dayLow": 271.745,
          "volume": 296072,
          "dayHigh": 276.06,
          "currency": "USD",
          "prevClose": 269.17,
          "week52Low": 209.38,
          "week52High": 293.72
        },
        "fundamentals": {
          "pe": 23.8026565464896,
          "beta": 0.621188731231074,
          "epsTTM": 10.54,
          "fcfTTM": 923300000,
          "growth": {
            "epsYoy": 0.1856017997750279,
            "revenueYoy": 0.07247346047705801
          },
          "sector": "Services-Medical Laboratories",
          "margins": {
            "net": 0.06282388526129433,
            "gross": 0.2875993606513901,
            "operating": 0.09924955381781432
          },
          "website": "https://labcorp.com",
          "industry": "Health care",
          "pegRatio": 1.28245828301995,
          "ebitdaTTM": 1952800000,
          "forwardPe": 14.1580135440181,
          "marketCap": 21700000000,
          "totalCash": 532300000,
          "totalDebt": 5584700000,
          "debtEquity": 0.647892062460846,
          "quickRatio": 0.9336284752966176,
          "revenueTTM": 13951700000,
          "companyName": "LABCORP HOLDINGS INC.",
          "priceToBook": 2.41680456655899,
          "currentRatio": 1.423941916061626,
          "dividendYield": 0.0115315244186617,
          "returnOnAssets": 0.04765477607964029,
          "returnOnEquity": 0.101684493839764,
          "analystOpinions": null,
          "businessSummary": "Labcorp Holdings Inc., operating under the brand name Labcorp, headquartered in Burlington, North Carolina, provides laboratory services used for diagnosis and healthcare decisions. It operates one of the largest clinical laboratory networks in the world and has operations in over 100 countries; although its operations are primarily in the U.S.",
          "enterpriseValue": 25925616000,
          "analystTargetLow": null,
          "analystTargetHigh": null,
          "analystTargetMean": null,
          "fullTimeEmployees": 70000,
          "sharesOutstanding": 82400000,
          "enterpriseToEbitda": 13.27612453912331,
          "analystTargetMedian": null,
          "enterpriseToRevenue": 1.858240644509271,
          "operatingCashflowTTM": 1640500000,
          "analystRecommendationKey": null
        }
      },
      "createdAt": "2026-04-09T05:21:17.775Z"
    },
    "results": [
      {
        "id": "cmnr14g6904smp658jkkjw843",
        "runId": "cmnr14g6704skp658hewo66ee",
        "modelId": "anthropic",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"LH\",\"currency\":\"USD\",\"current_price\":274.72,\"target_price_6m\":290,\"target_price_12m\":305,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Forward P/E of 14.2x signals significant earnings inflection ahead\",\"Diagnostics volume growth supported by aging US demographics\",\"Operating margin improvement path from 9.9% toward 13%+ achievable\",\"FCF yield ~4.3% with deleveraging optionality and buyback support\",\"Valuation discount to healthcare services peers offers upside cushion\"],\"key_drivers\":[{\"driver\":\"Earnings growth acceleration implied by forward P/E compression\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Organic diagnostic test volume growth driven by aging population\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Operating margin expansion via automation and cost discipline\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Share repurchase program reducing share count\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Net debt of ~$5B creates financial leverage risk\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Reimbursement rate pressure from government and managed care payers\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Low beta (0.62) provides defensive characteristics\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Competition from hospital in-sourcing and point-of-care testing\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Reimbursement cuts from CMS or large payer contract renegotiations\",\"Slower-than-expected margin improvement post Fortrea spin-off\",\"Rising labor costs in tight healthcare labor market\",\"Potential disruptive diagnostic technologies from new entrants\",\"Macroeconomic slowdown reducing elective testing volumes\"],\"assumptions\":{\"revenue_cagr_3y\":0.055,\"ebit_margin_target\":0.13,\"wacc\":0.085,\"terminal_multiple\":13.5},\"scenarios\":{\"bear\":{\"target_price\":235,\"prob\":0.2,\"notes\":\"Reimbursement headwinds and volume softness compress margins to 9%.\"},\"base\":{\"target_price\":305,\"prob\":0.55,\"notes\":\"Steady mid-single-digit revenue growth with margin expansion to ~12%.\"},\"bull\":{\"target_price\":345,\"prob\":0.25,\"notes\":\"Strong earnings beat cycle with margin reaching 14% and multiple re-rating.\"}},\"method_notes\":\"Blended EV/EBITDA and forward P/E valuation. Base assumes FY+1 EBITDA ~$2.2B at 12.5-13.5x plus margin expansion path. Forward P/E of 14.2x vs TTM 23.8x implies large earnings step-up which requires verification. 12M target ~$305 implies ~11% total return (incl. 1.2% div yield), consistent with BUY. Confidence moderate (0.62) due to gap between TTM and forward earnings needing confirmation. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "ai-equity-research-v1",
          "risks": [
            "Reimbursement cuts from CMS or large payer contract renegotiations",
            "Slower-than-expected margin improvement post Fortrea spin-off",
            "Rising labor costs in tight healthcare labor market",
            "Potential disruptive diagnostic technologies from new entrants",
            "Macroeconomic slowdown reducing elective testing volumes"
          ],
          "ticker": "LH",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.55,
              "notes": "Steady mid-single-digit revenue growth with margin expansion to ~12%.",
              "target_price": 305
            },
            "bear": {
              "prob": 0.2,
              "notes": "Reimbursement headwinds and volume softness compress margins to 9%.",
              "target_price": 235
            },
            "bull": {
              "prob": 0.25,
              "notes": "Strong earnings beat cycle with margin reaching 14% and multiple re-rating.",
              "target_price": 345
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 0.085,
            "revenue_cagr_3y": 0.055,
            "terminal_multiple": 13.5,
            "ebit_margin_target": 0.13
          },
          "key_drivers": [
            {
              "driver": "Earnings growth acceleration implied by forward P/E compression",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Organic diagnostic test volume growth driven by aging population",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Operating margin expansion via automation and cost discipline",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Share repurchase program reducing share count",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Net debt of ~$5B creates financial leverage risk",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Reimbursement rate pressure from government and managed care payers",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Low beta (0.62) provides defensive characteristics",
              "impact": "LOW",
              "direction": "POS"
            },
            {
              "driver": "Competition from hospital in-sourcing and point-of-care testing",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Blended EV/EBITDA and forward P/E valuation. Base assumes FY+1 EBITDA ~$2.2B at 12.5-13.5x plus margin expansion path. Forward P/E of 14.2x vs TTM 23.8x implies large earnings step-up which requires verification. 12M target ~$305 implies ~11% total return (incl. 1.2% div yield), consistent with BUY. Confidence moderate (0.62) due to gap between TTM and forward earnings needing confirmation. Not investment advice.",
          "current_price": 274.72,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Forward P/E of 14.2x signals significant earnings inflection ahead",
            "Diagnostics volume growth supported by aging US demographics",
            "Operating margin improvement path from 9.9% toward 13%+ achievable",
            "FCF yield ~4.3% with deleveraging optionality and buyback support",
            "Valuation discount to healthcare services peers offers upside cushion"
          ],
          "target_price_6m": 290,
          "target_price_12m": 305
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "anthropic",
            "webSearch": {
              "enabled": false,
              "maxToolCalls": 2,
              "disabledReason": null
            },
            "pauseTurns": 0,
            "stopReason": "end_turn"
          },
          "sanityIssues": []
        },
        "latencyMs": 39255,
        "createdAt": "2026-04-09T05:21:17.789Z",
        "usage": {
          "inputTokens": 3586,
          "outputTokens": 1867,
          "costUsd": 0.064605
        }
      },
      {
        "id": "cmnr14g6904spp658osmsbd8k",
        "runId": "cmnr14g6704skp658hewo66ee",
        "modelId": "deepseek.reasoner",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI_Equity_Model_v1\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"LH\",\n  \"currency\": \"USD\",\n  \"current_price\": 274.72,\n  \"target_price_6m\": 260.0,\n  \"target_price_12m\": 206.66,\n  \"recommendation\": \"SELL\",\n  \"confidence\": 0.65,\n  \"thesis_bullets\": [\n    \"LabCorp benefits from stable healthcare demand and global reach.\",\n    \"Revenue growth supported by aging population and diagnostic trends.\",\n    \"Operating margins face pressure from labor costs and competition.\",\n    \"Current valuation exceeds reasonable earnings-based fair value estimates.\",\n    \"Regulatory environment and reimbursement rates are key uncertainties.\"\n  ],\n  \"key_drivers\": [\n    { \"driver\": \"Healthcare demand growth\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n    { \"driver\": \"Pricing and reimbursement rates\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n    { \"driver\": \"Operational efficiency\", \"impact\": \"MED\", \"direction\": \"POS\" },\n    { \"driver\": \"Technological adoption in labs\", \"impact\": \"LOW\", \"direction\": \"POS\" },\n    { \"driver\": \"Competitive intensity\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n    { \"driver\": \"Regulatory changes\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n    { \"driver\": \"Economic conditions affecting patient visits\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n    { \"driver\": \"Debt management and interest expenses\", \"impact\": \"MED\", \"direction\": \"NEG\" }\n  ],\n  \"risks\": [\"Increased regulatory scrutiny\", \"Cyclical downturn in healthcare utilization\", \"Failure to improve margins\", \"Rising interest rates increasing debt costs\"],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.07,\n    \"ebit_margin_target\": 0.1,\n    \"wacc\": 0.08,\n    \"terminal_multiple\": 14\n  },\n  \"scenarios\": {\n    \"bear\": { \"target_price\": 180.0, \"prob\": 0.2, \"notes\": \"Severe margin compression and lower growth.\" },\n    \"base\": { \"target_price\": 206.66, \"prob\": 0.6, \"notes\": \"Moderate growth with stable margins.\" },\n    \"bull\": { \"target_price\": 250.0, \"prob\": 0.2, \"notes\": \"Strong revenue growth and margin expansion.\" }\n  },\n  \"method_notes\": \"DCF valuation using snapshot fundamentals. SELL due to overvaluation vs. growth assumptions. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "AI_Equity_Model_v1",
          "risks": [
            "Increased regulatory scrutiny",
            "Cyclical downturn in healthcare utilization",
            "Failure to improve margins",
            "Rising interest rates increasing debt costs"
          ],
          "ticker": "LH",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Moderate growth with stable margins.",
              "target_price": 206.66
            },
            "bear": {
              "prob": 0.2,
              "notes": "Severe margin compression and lower growth.",
              "target_price": 180
            },
            "bull": {
              "prob": 0.2,
              "notes": "Strong revenue growth and margin expansion.",
              "target_price": 250
            }
          },
          "confidence": 0.65,
          "assumptions": {
            "wacc": 0.08,
            "revenue_cagr_3y": 0.07,
            "terminal_multiple": 14,
            "ebit_margin_target": 0.1
          },
          "key_drivers": [
            {
              "driver": "Healthcare demand growth",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Pricing and reimbursement rates",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Operational efficiency",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Technological adoption in labs",
              "impact": "LOW",
              "direction": "POS"
            },
            {
              "driver": "Competitive intensity",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Regulatory changes",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Economic conditions affecting patient visits",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Debt management and interest expenses",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "DCF valuation using snapshot fundamentals. SELL due to overvaluation vs. growth assumptions. Not investment advice.",
          "current_price": 274.72,
          "recommendation": "SELL",
          "thesis_bullets": [
            "LabCorp benefits from stable healthcare demand and global reach.",
            "Revenue growth supported by aging population and diagnostic trends.",
            "Operating margins face pressure from labor costs and competition.",
            "Current valuation exceeds reasonable earnings-based fair value estimates.",
            "Regulatory environment and reimbursement rates are key uncertainties."
          ],
          "target_price_6m": 260,
          "target_price_12m": 206.66
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "endpoint": "https://api.deepseek.com/v1/chat/completions",
            "provider": "deepseek",
            "webSearch": {
              "enabled": false,
              "supported": false
            },
            "responseFormat": "json_object"
          },
          "sanityIssues": []
        },
        "latencyMs": 359,
        "createdAt": "2026-04-09T05:21:17.789Z",
        "usage": {
          "inputTokens": 2100,
          "outputTokens": 5482,
          "costUsd": 0.00289
        }
      },
      {
        "id": "cmnr14g6904snp6580gcimcz6",
        "runId": "cmnr14g6704skp658hewo66ee",
        "modelId": "gemini.3-pro",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"Equity Research Analyst AI\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"LH\",\"currency\":\"USD\",\"current_price\":274.72,\"target_price_6m\":295.0,\"target_price_12m\":310.0,\"recommendation\":\"BUY\",\"confidence\":0.7,\"thesis_bullets\":[\"Dominant market share in clinical diagnostics provides stable cash flow.\",\"Expansion into high-growth specialty testing and companion diagnostics.\",\"Strategic partnerships with health systems drive volume and efficiency.\",\"Post-spin-off focus improves margins and capital allocation flexibility.\",\"Attractive valuation relative to historical multiples and industry peers.\"],\"key_drivers\":[{\"driver\":\"Diagnostic volume growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"PAMA reimbursement stability\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"M&A integration efficiency\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Labor cost inflation\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Specialty testing mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Health system outsourcing\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Regulatory changes in reimbursement rates.\",\"Intense competition from regional labs.\",\"Potential for labor shortages and wage pressure.\",\"Integration risks from recent acquisitions.\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.14,\"wacc\":0.085,\"terminal_multiple\":12.0},\"scenarios\":{\"bear\":{\"target_price\":245.0,\"prob\":0.2,\"notes\":\"Reimbursement cuts and higher labor costs compress margins.\"},\"base\":{\"target_price\":310.0,\"prob\":0.6,\"notes\":\"Steady volume growth and successful execution of specialty strategy.\"},\"bull\":{\"target_price\":350.0,\"prob\":0.2,\"notes\":\"Accelerated health system outsourcing and margin expansion.\"}},\"method_notes\":\"Valuation based on 16x forward P/E and DCF. BUY reflects ~13% upside. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "Equity Research Analyst AI",
          "risks": [
            "Regulatory changes in reimbursement rates.",
            "Intense competition from regional labs.",
            "Potential for labor shortages and wage pressure.",
            "Integration risks from recent acquisitions."
          ],
          "ticker": "LH",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Steady volume growth and successful execution of specialty strategy.",
              "target_price": 310
            },
            "bear": {
              "prob": 0.2,
              "notes": "Reimbursement cuts and higher labor costs compress margins.",
              "target_price": 245
            },
            "bull": {
              "prob": 0.2,
              "notes": "Accelerated health system outsourcing and margin expansion.",
              "target_price": 350
            }
          },
          "confidence": 0.7,
          "assumptions": {
            "wacc": 0.085,
            "revenue_cagr_3y": 0.05,
            "terminal_multiple": 12,
            "ebit_margin_target": 0.14
          },
          "key_drivers": [
            {
              "driver": "Diagnostic volume growth",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "PAMA reimbursement stability",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "M&A integration efficiency",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Labor cost inflation",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Specialty testing mix",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Health system outsourcing",
              "impact": "MED",
              "direction": "POS"
            }
          ],
          "method_notes": "Valuation based on 16x forward P/E and DCF. BUY reflects ~13% upside. Not investment advice.",
          "current_price": 274.72,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Dominant market share in clinical diagnostics provides stable cash flow.",
            "Expansion into high-growth specialty testing and companion diagnostics.",
            "Strategic partnerships with health systems drive volume and efficiency.",
            "Post-spin-off focus improves margins and capital allocation flexibility.",
            "Attractive valuation relative to historical multiples and industry peers."
          ],
          "target_price_6m": 295,
          "target_price_12m": 310
        },
        "errorsJson": {
          "attempts": [
            {
              "error": "not_json_object: Output must be a single JSON object (no markdown/code fences, no extra text).",
              "attempt": 0,
              "rawOutputTruncated": "{\n  \"model\": \"Equity Research Analyst AI\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"LH\",\n  \"currency\": \"USD\",\n  \"current_price\": 274.72,\n  \"target_price_6m\": 295.0,\n  \"target_price_12m\": 310.0,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.7,\n  \"thesis_bullets\": [\n    \"Dominant market share in clinical diagnostics provides stable cash flow.\",\n    \"Expansion into high-growth specialty testing and companion diagnostics.\",\n    \"Strategic partnerships with health systems drive volume and efficiency.\",\n    \"Post-spin-off focus improves margins and capital allocation flexibility.\",\n    \"Attractive valuation relative to historical multiples and industry peers.\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Diagnostic volume growth\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"PAMA reimbursement stability\","
            },
            {
              "error": "not_json_object: Output must be a single JSON object (no markdown/code fences, no extra text).",
              "attempt": 1,
              "rawOutputTruncated": "{\n  \"model\": \"Equity Research Analyst AI\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"LH\",\n  \"currency\": \"USD\",\n  \"current_price\": 274.72,\n  \"target_price_6m\": 295.0,\n  \"target_price_12m\": 310.0,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.7,\n  \"thesis_bullets\": [\n    \"Dominant market share in clinical diagnostics provides stable cash flow.\",\n    \"Expansion into high-growth specialty testing and companion diagnostics.\",\n    \"Strategic partnerships with health systems drive volume and efficiency.\",\n    \"Post-spin-off focus improves margins and capital allocation flexibility.\",\n    \"Attractive valuation relative to historical multiples and industry peers.\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Diagnostic volume growth\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"PAMA reimbursement stability"
            }
          ],
          "providerMeta": {
            "model": "gemini-3-flash-preview",
            "provider": "gemini",
            "webSearch": {
              "used": false,
              "allowed": false,
              "enabled": false,
              "requested": false,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 15020,
        "createdAt": "2026-04-09T05:21:17.789Z",
        "usage": {
          "inputTokens": 2794,
          "outputTokens": 462,
          "costUsd": 0.011132
        }
      },
      {
        "id": "cmnr14g6904slp658shgpl7fn",
        "runId": "cmnr14g6704skp658hewo66ee",
        "modelId": "openai.gpt-5.4",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"LH\",\"currency\":\"USD\",\"current_price\":274.72,\"target_price_6m\":286.0,\"target_price_12m\":289.0,\"recommendation\":\"HOLD\",\"confidence\":0.63,\"thesis_bullets\":[\"Core diagnostics demand supports resilient mid-single-digit revenue growth.\",\"Forward P/E looks reasonable, but EV/EBITDA already discounts stability.\",\"Margin recovery and LaunchPad savings can lift earnings faster than sales.\",\"Balance sheet leverage limits valuation rerating versus asset-light peers.\",\"Defensive healthcare profile warrants ownership, but upside appears modest.\"],\"key_drivers\":[{\"driver\":\"Routine testing volumes\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Biopharma lab demand\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Cost productivity execution\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Payer reimbursement pressure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Leverage reduction\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Hospital outreach wins\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Labor and logistics costs\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Acquisition integration\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Medicare or commercial reimbursement cuts\",\"Biopharma and central-lab demand softness\",\"Execution miss on productivity savings\",\"Higher debt costs or slower deleveraging\"],\"assumptions\":{\"revenue_cagr_3y\":5.5,\"ebit_margin_target\":11.5,\"wacc\":8.0,\"terminal_multiple\":12.5},\"scenarios\":{\"bear\":{\"target_price\":245.0,\"prob\":0.25,\"notes\":\"Reimbursement and biopharma weakness offset cost savings.\"},\"base\":{\"target_price\":289.0,\"prob\":0.5,\"notes\":\"Stable volume growth and moderate margin expansion drive fair value.\"},\"bull\":{\"target_price\":330.0,\"prob\":0.25,\"notes\":\"Stronger productivity and specialty mix expand margins faster.\"}},\"method_notes\":\"Used snapshot quote/fundamentals as authoritative baseline. 12M target reflects a blended earnings/multiple view anchored on assumed 3Y growth, margin recovery and a 12.5x terminal EBIT multiple; fair value is only modestly above price, so HOLD. not investment advice\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "AI Model Recommendation v2",
          "risks": [
            "Medicare or commercial reimbursement cuts",
            "Biopharma and central-lab demand softness",
            "Execution miss on productivity savings",
            "Higher debt costs or slower deleveraging"
          ],
          "ticker": "LH",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Stable volume growth and moderate margin expansion drive fair value.",
              "target_price": 289
            },
            "bear": {
              "prob": 0.25,
              "notes": "Reimbursement and biopharma weakness offset cost savings.",
              "target_price": 245
            },
            "bull": {
              "prob": 0.25,
              "notes": "Stronger productivity and specialty mix expand margins faster.",
              "target_price": 330
            }
          },
          "confidence": 0.63,
          "assumptions": {
            "wacc": 8,
            "revenue_cagr_3y": 5.5,
            "terminal_multiple": 12.5,
            "ebit_margin_target": 11.5
          },
          "key_drivers": [
            {
              "driver": "Routine testing volumes",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Biopharma lab demand",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Cost productivity execution",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Payer reimbursement pressure",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Leverage reduction",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Hospital outreach wins",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Labor and logistics costs",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Acquisition integration",
              "impact": "LOW",
              "direction": "NEG"
            }
          ],
          "method_notes": "Used snapshot quote/fundamentals as authoritative baseline. 12M target reflects a blended earnings/multiple view anchored on assumed 3Y growth, margin recovery and a 12.5x terminal EBIT multiple; fair value is only modestly above price, so HOLD. not investment advice",
          "current_price": 274.72,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Core diagnostics demand supports resilient mid-single-digit revenue growth.",
            "Forward P/E looks reasonable, but EV/EBITDA already discounts stability.",
            "Margin recovery and LaunchPad savings can lift earnings faster than sales.",
            "Balance sheet leverage limits valuation rerating versus asset-light peers.",
            "Defensive healthcare profile warrants ownership, but upside appears modest."
          ],
          "target_price_6m": 286,
          "target_price_12m": 289
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "openai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "resp_0e1021581726efa40069d75ac52bf8819697839b8872031bb4",
            "reasoningEffort": "medium",
            "structuredOutputs": {
              "used": true,
              "requested": true,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 25625,
        "createdAt": "2026-04-09T05:21:17.789Z",
        "usage": {
          "inputTokens": 2368,
          "outputTokens": 1364,
          "costUsd": 0.02324
        }
      },
      {
        "id": "cmnr14g6904sop658j5a91d4f",
        "runId": "cmnr14g6704skp658hewo66ee",
        "modelId": "xai.grok-4.20-reasoning",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI Equity Analyst\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"LH\",\n  \"currency\": \"USD\",\n  \"current_price\": 274.72,\n  \"target_price_6m\": 280,\n  \"target_price_12m\": 288,\n  \"recommendation\": \"HOLD\",\n  \"confidence\": 0.62,\n  \"thesis_bullets\": [\n    \"Stable testing demand supports revenue visibility\",\n    \"Forward P/E of 14x appears fair for growth\",\n    \"Efficiency gains aid operating margin expansion\",\n    \"High debt load adds financial risk\",\n    \"Competition limits pricing power and upside\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Lab testing volumes\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Operating efficiency gains\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Competitive pressure\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Debt and interest costs\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Esoteric test growth\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Healthcare utilization\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"M&A execution\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Reimbursement rates\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    }\n  ],\n  \"risks\": [\n    \"Competition from Quest Diagnostics\",\n    \"Volume declines in economic downturns\",\n    \"Regulatory changes to reimbursements\",\n    \"Rising interest expenses on debt\",\n    \"M&A integration challenges\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.05,\n    \"ebit_margin_target\": 0.12,\n    \"wacc\": 0.085,\n    \"terminal_multiple\": 14\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 240,\n      \"prob\": 0.3,\n      \"notes\": \"Weak volumes and margin erosion from competition.\"\n    },\n    \"base\": {\n      \"target_price\": 288,\n      \"prob\": 0.5,\n      \"notes\": \"Moderate growth and successful efficiency programs.\"\n    },\n    \"bull\": {\n      \"target_price\": 330,\n      \"prob\": 0.2,\n      \"notes\": \"Strong demand and accretive acquisitions boost performance.\"\n    }\n  },\n  \"method_notes\": \"DCF with 5% rev CAGR, 12% EBIT margin, 8.5% WACC, 14x terminal; cross-checked with forward EV/EBITDA. Modest upside and mixed evidence support HOLD. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "AI Equity Analyst",
          "risks": [
            "Competition from Quest Diagnostics",
            "Volume declines in economic downturns",
            "Regulatory changes to reimbursements",
            "Rising interest expenses on debt",
            "M&A integration challenges"
          ],
          "ticker": "LH",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Moderate growth and successful efficiency programs.",
              "target_price": 288
            },
            "bear": {
              "prob": 0.3,
              "notes": "Weak volumes and margin erosion from competition.",
              "target_price": 240
            },
            "bull": {
              "prob": 0.2,
              "notes": "Strong demand and accretive acquisitions boost performance.",
              "target_price": 330
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 0.085,
            "revenue_cagr_3y": 0.05,
            "terminal_multiple": 14,
            "ebit_margin_target": 0.12
          },
          "key_drivers": [
            {
              "driver": "Lab testing volumes",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Operating efficiency gains",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Competitive pressure",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Debt and interest costs",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Esoteric test growth",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Healthcare utilization",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "M&A execution",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Reimbursement rates",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "DCF with 5% rev CAGR, 12% EBIT margin, 8.5% WACC, 14x terminal; cross-checked with forward EV/EBITDA. Modest upside and mixed evidence support HOLD. Not investment advice.",
          "current_price": 274.72,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Stable testing demand supports revenue visibility",
            "Forward P/E of 14x appears fair for growth",
            "Efficiency gains aid operating margin expansion",
            "High debt load adds financial risk",
            "Competition limits pricing power and upside"
          ],
          "target_price_6m": 280,
          "target_price_12m": 288
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "xai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "876a83ae-593f-9a31-b4ca-9cbf8ca06750",
            "usedFallbackChatCompletions": false
          },
          "sanityIssues": []
        },
        "latencyMs": 21494,
        "createdAt": "2026-04-09T05:21:17.789Z",
        "usage": {
          "inputTokens": 2709,
          "outputTokens": 3588,
          "costUsd": 0.061947
        }
      }
    ]
  }
}